首页> 美国卫生研究院文献>Open Forum Infectious Diseases >A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort

【2h】

A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort

机译：在艾滋病毒人员人民长期使用达尔努维尔病毒学失败患者患者的低水平的达尔努纳夫抗性突变出血。 ANRS CO3 AQUITAINE COHORT

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Open Forum Infectious Diseases
作者
Hélène Chaussade; Camille Tumiotto; Fabien Le Marec; Olivier Leleux; Lucile Lefèvre; Estibaliz Lazaro; Marie-Edith Lafon; Elsa Nyamankolly; Pierre Duffau; Didier Neau; Pantxika Bellecave; Fabrice Bonnet;
展开▼
作者单位

展开▼
年(卷),期 2020(7),12
年度 2020
页码 ofaa567
总页数 8
原文格式 PDF
正文语种
中图分类病毒传染病;
关键词
darunavir; HIV-1; genotype; mutation rate;

机译：Darunavir;HIV-1;基因型;突变率;
入库时间 2022-08-21 12:03:02

相似文献

外文文献

1. Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters [J] . DaillyE., RodallecA., AllavenaC., Fundamental & clinical pharmacology. . 2012,第4期

机译：感染HIV的患者对darunavir的病毒学应答与darunavir耐药相关的突变有关，该突变已通过具有积极影响的突变计数进行校正，并且与药理学和病毒学/药理学联合指标无关
2. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART [J] . Lambert-Niclot S., George E. C., Pozniak A., The Journal of Antimicrobial Chemotherapy . 2016,第4期

机译：NEAT 001 / ANRS 143试验中对病毒学失败的抗逆转录病毒耐药性：作为第一线抗病毒药物，raltegravir加darunavir / ritonavir或tenofovir / emtricitabine加darunavir / ritonavir
3. Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART [J] . Lambert-Niclot S., George E. C., Pozniak A., The Journal of Antimicrobial Chemotherapy . 2016,第4期

机译：在整齐的001 / ANRS 143试验中的病毒学衰竭处的抗逆转录病毒抗病病毒病毒病毒病毒病毒血管抗性：RARTEGRAVIR PLUS Darunavir / Ritonavir或Tenofovir / Emtricisabine Plus Darunavir / Ritonavir作为一线艺术
4. Virological and immunological response in HIV-1-infected patients with multiple treatment failures receiving raltegravir and optimized background therapy ANRS CO3 Aquitaine Cohort [O] . Linda Wittkop, Dominique Breilh, Daniel Da-Silva, -1

机译：在接受raltegravir和优化背景治疗的AN-1 CO3阿基坦队列研究中多次治疗失败的HIV-1感染患者的病毒学和免疫学应答
5. Incidence and Risk Factors for Severe Bacterial Infections in People Living with HIV. ANRS CO3 Aquitaine Cohort, 2000-2012. [O] . Amandine Collin, Fabien Le Marec, Marie-Anne Vandenhende, 2016

机译：艾滋病病毒感染者严重细菌感染的发病率和危险因素。 aNRs CO3 aquitaine Cohort，2000-2012。

A Low Level of Darunavir Resistance–Associated Mutation Emergence in Patients With Virological Failure During Long-term Use of Darunavir in People With HIV. The ANRS CO3 Aquitaine Cohort

著录项

相似文献

相关主题

期刊订阅